6-Aminoindole

• Catalog No.: 630721
• CAS Number: 5318-27-4
• M. F.: C8H8N2
• M. W.: 132.16252
• Purity: 97%

SYNONYMS

• Title: 6-氨基吲哚
• IUPAC name: 1H-indol-6-amine
• IUPAC Traditional name: 1H-indol-6-amine
• Synonyms: Indol-6-ylamine; NSC 82379

DATABASE IDS

• CAS Number: 5318-27-4
• PubChem SID: 24882337
• MDL Number: MFCD02093959

PROPERTIES

• Empirical Formula (Hill Notation): C8H8N2
• Purity: 97%
• Melting Point: 75-79 °C
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H315-H319-H335
• European Hazard Symbols: Harmful (Xn)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P261-P305 + P351 + P338
• Risk Statements: 22-36/37/38
• Safety Statements: 26-36
• Storage Temperature: -20°C
• German water hazard class: 3

DETAILS

Description (English)

Packaging
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Inhibitors of mammalian target of rapamycin (mTOR ) protein1
• Inhibitors of the AcrAB-TolC efflux pump2
• Inhibitors of Gli1-mediated transcription in the Hedgehog pathway3
• Potent DNA-topoisomerase II poisons and anti-MDR agents4
• Protein kinase C θ (PKCθ) inhibitors5
• Piperidine carboxamide as transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists6
• Potent and selective blockers of the Nav1.8 sodium channel as potential analgesics for the treatment of neuropathic and inflammatory pain7
• 5,6-fused heteroaromatic ureas as TRPV1 antagonists8
• Allosteric enhancers of the A3 adenosine receptor9
• Human liver glycogen phosphorylase (HLGP) inhibitors for the treatment of type 2 diabetes10

Description (简体中文)

包装
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Inhibitors of mammalian target of rapamycin (mTOR ) protein1
• Inhibitors of the AcrAB-TolC efflux pump2
• Inhibitors of Gli1-mediated transcription in the Hedgehog pathway3
• Potent DNA-topoisomerase II poisons and anti-MDR agents4
• Protein kinase C θ (PKCθ) inhibitors5
• Piperidine carboxamide as transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists6
• Potent and selective blockers of the Nav1.8 sodium channel as potential analgesics for the treatment of neuropathic and inflammatory pain7
• 5,6-fused heteroaromatic ureas as TRPV1 antagonists8
• Allosteric enhancers of the A3 adenosine receptor9
• Human liver glycogen phosphorylase (HLGP) inhibitors for the treatment of type 2 diabetes10